DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

2 API Suppliers, 1 USDMF, 1 Listed Suppliers

2 API Suppliers
1 USDMF
1 Listed Suppliers

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

0 DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Salinosporamide a, 437742-34-2, Npi-0052, (-)-salinosporamide a, Npi 0052, Ml 858

Molecular Formula

C₁₅H₂₀ClNO₄

Molecular Weight

313.77 g/mol

InChI Key

NGWSFRIPKNWYAO-SHTIJGAHSA-N

FDA UNII

703P9YDP7F

Marizomib is a naturally-occurring salinosporamide, isolated from the marine actinomycete Salinospora tropica, with potential antineoplastic activity. Marizomib irreversibly binds to and inhibits the 20S catalytic core subunit of the proteasome by covalently modifying its active site threonine residues; inhibition of ubiquitin-proteasome mediated proteolysis results in an accumulation of poly-ubiquitinated proteins, which may result in the disruption of cellular processes, cell cycle arrest, the induction of apoptosis, and the inhibition of tumor growth and angiogenesis. This agent more may more potent and selective than the proteasome inhibitor bortezomib.

1 2D Structure

Marizomib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(1R,4R,5S)-4-(2-chloroethyl)-1-[(S)-[(1S)-cyclohex-2-en-1-yl]-hydroxymethyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione

2.1.2 InChI

InChI=1S/C15H20ClNO4/c1-14-10(7-8-16)12(19)17-15(14,13(20)21-14)11(18)9-5-3-2-4-6-9/h3,5,9-11,18H,2,4,6-8H2,1H3,(H,17,19)/t9-,10+,11+,14+,15+/m1/s1

2.1.3 InChI Key

NGWSFRIPKNWYAO-SHTIJGAHSA-N

2.1.4 Canonical SMILES

CC12C(C(=O)NC1(C(=O)O2)C(C3CCCC=C3)O)CCCl

2.1.5 Isomeric SMILES

C[C@]12[C@H](C(=O)N[C@]1(C(=O)O2)[C@H]([C@H]3CCCC=C3)O)CCCl

2.2 Other Identifiers

2.2.1 UNII

703P9YDP7F

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Homosalinosporamide A

2. Npi 0052

3. Npi-0052

4. Salinosporamide A

2.3.2 Depositor-Supplied Synonyms

1. Salinosporamide A

2. 437742-34-2

3. Npi-0052

4. (-)-salinosporamide A

5. Npi 0052

6. Ml 858

7. Salinosporamide A (npi-0052, Marizomib)

8. 703p9ydp7f

9. Chebi:48045

10. (1r,4r,5s)-4-(2-chloroethyl)-1-((s)-((s)-cyclohex-2-en-1-yl)(hydroxy)methyl)-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione

11. (1r,4r,5s)-4-(2-chloroethyl)-1-[(s)-(1s)-cyclohex-2-en-1-yl(hydroxy)methyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione

12. Marizomib [usan:inn]

13. Marizomibum

14. Unii-703p9ydp7f

15. Homosalinosporamide A

16. Marizomib [inn]

17. Marizomib (usan/inn)

18. Marizomib [usan]

19. Marizomib [who-dd]

20. Schembl151667

21. Salinosporamide A [mi]

22. Chembl371405

23. Dtxsid00904019

24. (1s,2r,5r)-2-(2-chloroethyl)-5-[(s)-[(1s)-cyclohex-2-en-1-yl]-hydroxymethyl]-1-methyl-7-oxa-4-azabicyclo[3.2.0]heptane-3,6-dione

25. Ex-a3259

26. Zinc3990364

27. Bdbm50398608

28. Akos027323566

29. Db11762

30. Hy-10985

31. Cs-0002986

32. D09640

33. A872651

34. Q7404722

35. (1r,4r,5s)-4-(2-chloroethyl)-1-((s)-((1s)-cyclohex-2-en-1-yl)hydroxymethyl)-5-methyl- 6-oxa-2-azabicyclo(3.2.0)heptane-3,7-dione

36. (1r,4r,5s)-4-(2-chloroethyl)-1-((s)-((s)-cyclohex-2-enyl)(hydroxy)methyl)-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione

37. (1r,4r,5s)-4-(2-chloroethyl)-1-[(s)-[(1s)-cyclohex-2-en-1-yl]-hydroxymethyl]-5-methyl-6-oxa-2-azabicyclo[3.2.0]heptane-3,7-dione

38. 6-oxa-2-azabicyclo(3.2.0)heptane-3,7-dione, 4-(2-chloroethyl)-1-((s)-(1s)-2-cyclohexen-1-ylhydroxymethyl)-5-methyl-, (1r,4r,5s)-

39. 6-oxa-2-azabicyclo(3.2.0)heptane-3,7-dione, 4-(2-chloroethyl)-1-((s)-(1s)-2-cyclohexen-1-ylhydroxymethyl)-5-methyl-, (1r,4r,5s)-

2.4 Create Date

2006-10-26

3 Chemical and Physical Properties

Molecular Formula	C₁₅H₂₀ClNO₄
Molecular Weight	313.77 g/mol
XLogP3	1.8
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	4
Exact Mass	313.1080858 g/mol
Monoisotopic Mass	313.1080858 g/mol
Topological Polar Surface Area	75.6 Å²
Heavy Atom Count	21
Formal Charge	0
Complexity	508
Isotope Atom Count	0
Defined Atom Stereocenter Count	5
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1